EPISODE · Jun 6, 2025 · 17 MIN
Lymphoma SIG Podcast 11 - BSH 2025 Highlights - Dr Sridhar Chaganti updates regarding large B cell lymphoma
from The BSH Guidelines Official Podcast · host British Society for Haematology
In this episode, Dr Sridhar Chaganti shares with us the highlights in large B-cell lymphoma from BSH 2025, including real-world experience in the use of bispecific antibodies and the recent NICE approval of Lisocel as second line treatment. Dr Chaganti is a Consultant Haemato-oncologist at the University Hospital in Birmingham, with an interest in lymphomas, ALL, stem cell transplantation and immune effector cell therapies including CART cell therapy. He is the chair of the high-grade lymphoma study group and co-chairs the national CAR-T panel.
What this episode covers
In this episode, Dr Sridhar Chaganti shares with us the highlights in large B-cell lymphoma from BSH 2025, including real-world experience in the use of bispecific antibodies and the recent NICE approval of Lisocel as second line treatment. Dr Chaganti is a Consultant Haemato-oncologist at the University Hospital in Birmingham, with an interest in lymphomas, ALL, stem cell transplantation and immune effector cell therapies including CART cell therapy. He is the chair of the high-grade lymphoma study group and co-chairs the national CAR-T panel.
NOW PLAYING
Lymphoma SIG Podcast 11 - BSH 2025 Highlights - Dr Sridhar Chaganti updates regarding large B cell lymphoma
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.